The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated ...

A major focus of the guideline is earlier intervention through healthy lifestyle changes, starting in childhood. Early consideration of pharmacotherapy in youth with familial hypercholesterolemia (FH) ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes ...

The new ACC/AHA Guideline for the Evaluation and Management of Acute Pulmonary Embolism (PE) in Adults is a de novo document offering comprehensive, evidence‑based recommendations for the evaluation, ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease ...

Tirzepatide was noninferior to dulaglutide among patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), with respect to the primary composite outcome of cardiovascular ...

Light-to-moderate alcohol consumption is associated with increases in blood pressure (BP) and stopping drinking – even drinking less – may lead to clinically meaningful BP reductions, according to a ...

Oral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the ...

The American College of Cardiology has issued a Concise Clinical Guidance (CCG) document to aid clinicians in the use of medication for weight management in patients where treatment may provide ...

Consumption of ultra-processed foods, such as sugar-sweetened beverages, potato chips and packaged cookies, may be associated with adverse health outcomes, according to research being presented at the ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

More time spent sitting, reclining or lying down during the day may increase the risk of cardiovascular disease (CVD) and death, according to a study in JACC, the flagship journal of the American ...